

Cite this: *RSC Adv.*, 2018, 8, 24750

Hematite iron oxide nanoparticles: apoptosis of myoblast cancer cells and their arithmetical assessment†

Rizwan Wahab,^{ID}*^{ab} Farheen Khan*^c and Abdulaziz A. Al-Khedhairy^a

Hematite (α -Fe₂O₃) forms iron oxide nanoparticles (NPs) which are thermally stable and have various electrochemical and optochemical applications. Due to their wide applicability, the present work was designed to form the hematite phase of iron oxide (α -Fe₂O₃NPs) NPs prepared *via* a solution process. Their cytological performance was checked with C2C12 cells. The crystalline property of the NPs was examined with X-ray diffraction patterns (XRD) and it was found that the size of the particles formed ranged from 12 to 15 nm. Structural information was also identified *via* field emission scanning electron microscopy (FESEM) and transmission electron microscopy (TEM), which again confirmed that the size of each NP is about 12–15 nm. Surface topographical analysis was done *via* atomic force microscopy (AFM), which reveals that the size of the distance between two particles is in the range of 12 ± 3 nm. The C2C12 cells were cultured in a humidified environment with 5% CO₂ and were checked *via* a microscope. The α -Fe₂O₃NPs were used for cytotoxic evaluation against C2C12 cells. A MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to check the viability of cells in a dose-dependent (100 ng mL⁻¹, 500 ng mL⁻¹ or 1000 ng mL⁻¹) manner. The morphology of the cells under the influence of α -Fe₂O₃NPs for live and dead cells in a wet environment was confirmed *via* confocal laser scanning microscopy (CLSM). The apoptosis caused due to the α -Fe₂O₃NPs was evaluated in presence of caspases 3/7 with GAPDH genes, which confirmed the upregulation that is responsible in caspase 3/7 genes, with treatment of C2C12 at low (500 ng mL⁻¹) and high (1000 ng mL⁻¹) doses of α -Fe₂O₃NPs. Analytical studies were also performed to authenticate the obtained data for α -Fe₂O₃NPs using parameters such as precision, accuracy, linearity, limits of detection (LOD) and limit of quantitation (LOQ), quantitative recoveries and relative standard deviation (RSD). The analyses play a significant role in investigating the large effect of α -Fe₂O₃NPs on C2C12 cells.

Received 26th March 2018

Accepted 9th June 2018

DOI: 10.1039/c8ra02613k

rsc.li/rsc-advances

Introduction

Magnetic oxide nanoparticles (NPs) have unique physicochemical properties, and have attracted great interest in recent years. Among the different forms of iron oxide are maghemite (γ -Fe₂O₃), magnetite (Fe₃O₄) and goethite (α -FeOOH) *etc.*^{1–3} The hematite (α -Fe₂O₃) form of iron oxide is thermodynamically stable and has n-type semi-conductor properties.⁴ The low-cost processing and auspicious band-gap (2.1–2.2 eV) of α -Fe₂O₃ make it an excellent material and it can be utilized in various fields, such as catalysis,^{5,6} pigments,⁷ electrocatalysis,⁸ photocatalysis,⁹ electrochemical sensors,¹⁰ gas sensors,¹¹ solar cells,¹²

sorbants,¹³ electrode materials,¹⁴ lithium ion battery electrodes,¹⁵ and storage materials.¹⁶ The low band gap enables greater possibility for the absorption of light in the visible range compared to TiO₂NPs.¹⁷ Various ways have been adopted to prepare different types of iron oxide NPs, such as sol-gel,¹⁸ surfactant assisted,¹⁹ hydrothermal,²⁰ thermal oxidation,²¹ microwave,²² mechanical milling *etc.*²³ Hematite nanostructures can be synthesised with various physicochemical parameters by changing their size, precursor concentration, the pH of the solution, surface properties *etc.*²⁴ Several researchers have drawn attention to this direction, such as Lassoued *et al.* who described the effect of a change in concentration of the precursor solution on the formation of hematite nanoparticles, checking the size of the nanoparticles, their morphology and optical properties,²⁵ whereas in another report, the sizes of the nanoparticles were varied by heating, when they formed different phases of iron, (γ -Fe₂O₃) or (α -Fe₂O₃).²⁶ Hematite nanoparticles (α -Fe₂O₃) can also be synthesised *via* controlled precipitation methods with variation in the precursor's precipitation methods using inorganic metal salts or washing the material, and calcination also affected the size of the

^aZoology Department, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia. E-mail: rwhab05@gmail.com; Tel: +966-536023284

^bAl-Jeraisy, chair for DNA research, Zoology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

^cChemistry Department, Faculty of Science, Taibah University, Yanbu, Saudi Arabia. E-mail: kharfarheenchem@gmail.com; Tel: +966-571603069

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra02613k



nanostructures. This is dependent upon the synthetic method adopted and their processes can be optimized to develop high-quality nanoparticles.²⁷ The size distribution also changes with a variation in pH and has the property of forming α -Fe₂O₃ NPs.²⁸ Preparation at low cost, with good quality, *via* a facile approach is a challenging task that can be met *via* a solution process. Considering the physical, optical and chemical applications of hematite (α -Fe₂O₃) NPs, they have been utilized as biomedical materials in drug delivery, chemotherapy, MRI, antibacterial agents *etc.* The magnetic nanoparticles can be functionalized with various biological molecules, such as proteins or nucleic acids, *via* physicochemical conjugations.^{29,30} The magnetic NPs (α -Fe₂O₃) have an excellent biocompatibility and thus could be used in many *in vitro* and *in vivo* imaging studies.³¹

For various physicochemical applications of hematite (α -Fe₂O₃) NPs, very limited information is available about using nanostructures as anticancer agents. To control the proliferation rate of cancer cells and to understand their role, researchers have utilized nanostructures against cancer cells. For example, 30 nm size NPs were exploited as an anticancer agent against lung cancer cells (HepG2) in a dose-dependent manner.³² In another report, magnetic NPs work in long-term corresponding imaging, in modalities and transplanted cells which could be used in MRI or CT in preclinical animal models.³³ Among these NPs, the core-shell shaped nanostructures of hematite (thickness \sim 10–20 nm, diameter \sim 80–100 nm) embedded with plate-like structures exhibit low cytotoxicity levels on human lung fibroblast (MRC5) cell lines for biomedical applications.³⁴ The hematite (α -Fe₂O₃) nanoparticles were utilized on the Madin-Darby Canine Kidney (MDCK) cell line to find out the degree of internalization into the cells, generating free radical species which influence the cytotoxic effects.³⁵ The α -Fe₂O₃ nanoparticles were also utilized to check their cytotoxic influence on human breast cancer MCF-7 cells.³⁶ Recent advances demonstrate that magnetic nanoparticles have the ability to work as drug delivery systems, and to deliver the NPs to the cells and specified organs. Rat stem cells were magnetized and the iron oxide NPs were used on the upper hemisphere of a rodent retina.³⁷

The present work demonstrates the utilization of chemically synthesized hematite (α -Fe₂O₃) for its potential cytological effect on myoblast (C2C12) cancer cells, which has not yet been explored under *in vitro* conditions. The crystalline character of the NPs was examined by looking at the XRD pattern, whereas the morphology of the NPs was evaluated *via* FESEM and TEM. The topographical evaluation was completed with AFM. The % cell viability was examined with an MTT assay in a dose-dependent manner and the morphological changes in cells were studied *via* inverted microscopy. Cell death with a dose-dependent incorporation of hematite (α -Fe₂O₃) NPs in a wet environment was also checked with CLSM. Apoptosis in cells with NPs and their genetic study were performed with caspases 3 and 7 with GAPDH genes. The acquired data was validated with statistical analytical parameters such as precision, accuracy, linearity, limits of detection (LOD) and limit of quantitation (LOQ), quantitative recoveries and relative standard deviation (RSD).

Materials and methods

Experimental

Synthesis of iron oxide (α -Fe₂O₃ NPs) nanoparticles. The synthesis of iron oxide (α -Fe₂O₃ NPs, hematite phase) NPs was accomplished using iron(III) nitrate nonahydrate (Fe(NO₃)₃·9H₂O), *n*-propylamine (CH₃-(CH₂)₂-NH₂) and sodium hydroxide (NaOH). The chemicals for the preparation of the NPs were purchased from the Aldrich Chemical Corporation (U.S.A) and used without further purification. In a typical experiment: Fe(NO₃)₃·9H₂O (3×10^{-2} M) and *n*-propyl amine (\sim 20%) were mixed in methanol (MeOH) under constant stirring, and after mixing a brown-colored solution appeared in the beaker. Into this colored solution, NaOH (0.1 M), was mixed and shaken each time for complete mixing. After the complete addition, the pH of the solution was checked *via* a pH meter (Cole Parmer, U.S.A.). Due to the increase in basicity of the solution, the pH reached 12.06. After complete mixing, the solution was transferred to a two-necked glass pot and was heated at \sim 90 °C for an hour (h). During this experiment, as the solution temperature rises, the color of the solution changes to dark brown. When the reaction process was complete, the product was separated by centrifugation (3000 rpm min⁻¹ for 5 min), and washed repeatedly with MeOH, ethanol and acetone to remove the chemical impurities. The obtained powdery material was dried at room temperature to avoid agglomeration of the particles. The dried NPs were further utilized for chemical, morphological and biological studies.

Characterization

The prepared NPs were analysed in terms of their morphological, chemical and topographical properties. The morphological observations of the prepared nanopowders were made by FE-SEM (Hitachi S-4700, Japan) and TEM (JEOL JEM JSM 2010, Japan). Apart from these characterizations, AFM was also utilized to check the surface topographical behaviour (horizontal, vertical and lateral size of grown NPs). For AFM (Veeco, USA) observations, the sample was prepared on the silicon substrate by dropping an liquid dispersion of NPs and dried at room temperature for about 30 min. The crystallinity, phases and size of the prepared powder was characterized by XRD with Cu_{K α} radiation ($\lambda = 1.54178$ Å, Rigaku, Japan) in the range of 20–80° with a 6° min⁻¹ scanning speed with 40 kV and 30 mA current. Fourier transform infrared spectroscopy (FTIR, PerkinElmer GX spectrophotometer) measurements were analysed in the range 4000–400 cm⁻¹.

Cell culture

The cancer cells (C2C12) were purchased from the American Type Culture collection (ATCC-CRL 1772; Bethesda, MD) and cultured in growth medium (Dulbecco's Modified Eagle's Medium, DM EM), which contains 10% fetal bovine serum (FBS), 100 IU mL⁻¹ penicillin, and 100 μ g mL⁻¹ streptomycin and incubated in a humidified incubator at 37 °C with 5% CO₂. The medium was changed every alternate day and the cells were subcultured with trypsin after they had passed 50–70% confluence.

Cell viability by MTT assay

The viability of the cells was checked with cell proliferation kit I (MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), a tetrazole, provided by ROCHE, Ltd, U.S.A.) according to the manufacturer's instructions. Briefly, the cell line was seeded into 96-well plates at 5×10^3 cells per well and the plate incubated overnight at 37 °C in a humidified incubator with 5% CO₂. The C2C12 cells were incubated with different concentration (100 ng mL⁻¹, 500 ng mL⁻¹ and 1000 ng mL⁻¹) of α Fe₂O₃NPs and returned to the incubator for 24 h, 48 h and 72 h. The cytotoxic assessment or mitochondrial dysfunction was evaluated by the use of MTT (~10–20 μ L added to each well and kept for ~3 h) salt/assays. The MTT salt reduces to form a purple formazan salt in the mitochondria of living cells. The stored stock MTT solution was added to the control and treated with NPs, and the cell samples were again incubated at 37 °C for 4 h. After the incubation, the samples were removed from the incubator and mixed with solubilizing buffer (DMSO, 100 μ L per well) solution. A purple color was visible at this stage, which deepened with pipetting. The control and treated samples were again incubated overnight to ensure that the formazan precipitate had dissolved. The measurement of the MTT assay was analyzed with an Elisa Reader (Bio Rad) at 570 nm. The UV-irradiation was provided by a deuterium and xenon lamp. The absorbances of the colored solutions were recorded at 570 nm by a spectrophotometer. The percentage (%) viability was calculated as follows:

$$\% \text{ Viability} = \frac{\text{OD (optical densities) in sample well}}{\text{OD in control well}} \times 100$$

Confocal scanning laser microscopy (CSLM) measurement

To find the dose-dependent cell deaths in a wet environment with prepared NPs, the cells (C2C12) were cultured and seeded (5×10^3 cell per well) into a confocal disk. The cells with α Fe₂O₃NPs were incubated (24 h) at 37 °C in a humidified environment with 5% CO₂. When the cells passed 50–70% confluence, the medium was removed from the confocal disk and PBS was added, gently but well shaken, and the buffer removed from the confocal disk. The cells were fixed using ethanol (70%, 200 μ L) and the solution retained for 10 min for complete fixation. The incubated cells were again washed using PBS, shaken gently, and the medium completely removed from the confocal disk. For the staining, the cells were mounted with propidium iodide (PI) with buffer solution and again incubated at 37 °C for 30 min in an incubator and again washed with buffer. The stained cells were covered with a cover slip.

mRNA extraction from C2C12 cells

Total RNA was extracted from the C2C12 cells after various treatments for set periods of time using Trizol (Sigma) according to the manufacturer's protocol. The purity of the total RNA was assessed by the ratio of optical density at 260 nm to that at 280 nm (acceptable values being between 1.6 and 2.1). First, strand cDNA

was synthesized from 1 μ g of the total RNA using M-MLV Reverse Transcriptase with Anchored Oligo d(T)12-18 Primer. Real-time PCR was performed using a cDNA equivalent of 10 ng of total RNA from each sample with primers specific for caspase 3/7 genes with a housekeeping gene GAPDH. The reaction was carried out in 10 μ L samples using SsoFast™ EvaGreen® Supermix (Bio-Rad) according to the manufacturers' instructions. Relative ratios were calculated based on the $2^{-\Delta\Delta CT}$ method. PCR was monitored using the CFX96™ Real-Time PCR Detection Systems (Bio-Rad).

Analytical determination

A concentration of α Fe₂O₃NPs of 1 μ g mL⁻¹ was employed against suspended solutions of cancer cells (C2C12), and the quantity determined by the analytical method. The recorded absorption spectra of α Fe₂O₃NPs, C2C12 and α Fe₂O₃NPs were measured at λ_{max} 230 and 440, 290, 350 nm, determined by a UV-visible spectrophotometer.

Statistical analysis

The obtained data is expressed as mean \pm SD. Statistical analysis was performed by Student *T*-tests. Results were considered significant when $P < 0.05$.

Result and discussion

X-ray diffraction pattern of α Fe₂O₃ NPs

The XRD spectrum shows a picture of the material crystallinity, phase and size of the prepared nanopowder. From a detailed observation of the obtained spectrum, it is evident from Fig. 1 that the prepared material is the hematite phase (α Fe₂O₃) of iron oxide NPs with the exact phases being compared with the available phase identification JCPDS card no. 39-1346. The peak positions, such as 23.70 (012), 32.70 (104), 35.10 (110), 40.40 (113), 43.35 (202), 49.05 (024), 53.60 (116), 57.1 (018), 62.0 (214), 63.70 (300), 69.02 (208), 71.65 (1010) and 75.10 (220), are clearly indexed with the phase of hematite (α Fe₂O₃) iron oxide. The average particle size of the prepared NPs is $\sim 12 \pm 3$ nm, as calculated by the Scherrer formula.³⁸ From the spectrum, it is evident that no hydroxide




Fig. 1 The X-ray diffraction pattern of iron oxide nanoparticles (α Fe₂O₃ hematite phase).




Fig. 4 The FTIR spectra of the prepared iron oxide nanoparticles ($\alpha\text{Fe}_2\text{O}_3$ hematite phase).

alters in shape and position due to presence of hydrogen bonding in an alcoholic medium. A sharp peak centred at 876 cm^{-1} is associated with the stretching mode of the nitrate (NO_3^-) group from iron nitrate.^{25–28} A curved and flattened peak around 541 cm^{-1} in the FTIR spectrum represents the formation of Fe–O and shows the metal oxide peak. The obtained functional information from FTIR justifies that the prepared nanostructures have a good chemical property and this is consistent with the XRD pattern data. We have not found any other residues because they were washed out during the washing of the prepared product with alcohol and acetone.

Anticipated chemical reaction mechanism for $\alpha\text{Fe}_2\text{O}_3$ NPs

On the basis of the chemical reaction used and observations such as the XRD, FE-SEM, TEM, AFM and FTIR findings, a chemical reaction mechanism is proposed for the formation of $\alpha\text{Fe}_2\text{O}_3$ NPs. In this experiment, when the iron(III) nitrate nonahydrate ($\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$) was dissolved in MeOH under continuous stirring and *n*-propylamine and NaOH were added to this suspension, it forms a clear solution without a precipitate at a pH of 12.06. At the desired refluxing temperature of $\sim 90\text{ }^\circ\text{C}$, a precipitate started to form in the refluxing pot. And it was completed in 60 min. As for the chemical reactions, it is assumed that the nitrate ($-\text{NO}_3$) group from iron(III) nitrate nonahydrate ($\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$) reacted with sodium (Na^+) ions due to the strong electro-negativity factor. The amine ($-\text{NH}_2$) chain from *n*-propylamine reacted with the iron (Fe^{3+}) ions and formed a long chain with the amine complex ($\text{FeN}-(\text{CH}_2)_2-\text{CH}_3$), which may be due to the decomposition of the hydrogen bond in the solution. As the reaction temperature rises, the hydroxyl (OH^-) ions from sodium react with the iron complex ($\text{FeN}-(\text{CH}_2)_2-\text{CH}_3$), and the (Fe^{3+}) ions react with the hydroxyl (ions), forming iron hydroxide ($\text{Fe}(\text{OH})_3$). This hydroxide ($\text{Fe}(\text{OH})_3$) molecule was further changed into iron oxide (Fe_2O_3) due to refluxing and drying with MeOH from the compound. The mechanism was also justified with the available FTIR data (Fig. 4). As found in previous literature, at a higher refluxing temperature hydroxide molecules change into pure oxide

material upon heating and drying. The product/residue formed from the reaction was leached out during washing, and centrifugation of the product.^{40,41}

Morphological evaluation (C2C12) and their interaction effect with $\alpha\text{Fe}_2\text{O}_3$ NPs

The C2C12 cells were cultured in a specified 75 mm^2 flask and grown at their confluence (50–70%). When the cells reached their optimum confluence (50–70%), they were again harvested with trypsin and treated with the prepared $\alpha\text{Fe}_2\text{O}_3$ NPs at different concentrations (100 ng mL^{-1} , 500 ng mL^{-1} and 1000 ng mL^{-1}). A control was also managed to check the difference between treated and untreated samples. The samples were incubated with 5% CO_2 at $37\text{ }^\circ\text{C}$ for different time (24, 48, and 72 h) periods (Fig. 5). Initially, no changes were observed in the culture medium but after 24 h, cells were seen to be mono nucleate and started to proliferate (48 h) and as the incubation time reached 72 h, the cells were damaged (Fig. 5). It is very clear from the images that as the concentration (100 ng mL^{-1} , 500 ng mL^{-1} and 1000 ng mL^{-1}) of NPs increases, the cells' viability was damaged by interaction with the prepared nanomaterial.^{42,43}

MTT assay or cytotoxicity calculations

The obtained MTT results showed that the % viable cells varied in a dose/concentration-dependent manner. The cell viabilities at concentrations of 100 ng mL^{-1} , 500 ng mL^{-1} and 1000 ng mL^{-1} were recorded as 87%, 55% and 48%, respectively, by MTT assay at 24 h. With an increase in incubation, a sequential change in cell viability was observed at 100 ng mL^{-1} , 500 ng mL^{-1} and 1000 ng mL^{-1} concentrations and was recorded as 60%, 50% and 3%, respectively, by MTT assay at 48 h. With a 72 h incubation period, a sudden drop in viability was observed for 100 ng mL^{-1} , 500 ng mL^{-1} and 1000 ng mL^{-1} concentrations to 57%, 41% and 31%, respectively, by MTT assay (Fig. 6). Similar results were also found with C2C12 cells with various concentrations using platinum quantum dots, gold nanoparticles and also metal oxide/zinc oxide




Fig. 5 Microscopic images of the effect on C2C12 of iron oxide $\alpha\text{Fe}_2\text{O}_3$ (hematite phase) nanoparticles at different concentrations and incubation times.

nanoparticles.^{40,42,43} The obtained result signifies that the prepared hematite NPs reduce the viability of cancer cells at different nanogram (100 ng mL^{-1} , 500 ng mL^{-1} and 1000 ng mL^{-1}) concentration levels for different incubation (24, 48 and 72 h) periods.

Caspase-3 and 7 activity effect with $\alpha\text{Fe}_2\text{O}_3$ NPs

The levels of mRNA in the presence of caspase 3 and 7 genes against C2C12 cells with the incorporation of $\alpha\text{Fe}_2\text{O}_3$ NPs (in the presence of GAPDH) were analyzed with RT-PCR. The cells were treated with NPs at defined (500 ng mL^{-1} & 1000 ng mL^{-1}) concentrations for two different incubation (24 & 72 h) periods. After analysis, the obtained data from PCR show that the levels of mRNA for the markers (caspase 3 and 7) were considerably changed in the cancer cells, which is due to exposure to $\alpha\text{Fe}_2\text{O}_3$ -NPs (Fig. 7 and 8, $p < 0.05$ for each). According to the obtained data, the genes' expressions for caspase 3 with $\alpha\text{Fe}_2\text{O}_3$ NPs at 100 ng mL^{-1} at 24 h incubation period were 1.32 and 2.51, respectively. The amounts of change at a high (1000 ng mL^{-1}) concentration of $\alpha\text{Fe}_2\text{O}_3$ -NPs with 72 h incubation period were 2.02 and 4.30 fold, respectively, defining a gradual change, due to the upregulation of the genes (Fig. 7). The quantitative real-time PCR results indicated that $\alpha\text{Fe}_2\text{O}_3$ -NPs show upregulation in the mRNA level of the cell cycle checkpoint of caspase 3 and 7.⁴⁴ The caspase activities correspond to the portion of apoptotic cells present in the naturally growing population due to natural aging in untreated cells.

The role of alteration in gene expression was associated with an untreated sample as a control or a signature control (GAPDH) for the knockdown data. Generally the prepared metal oxide nanostructures (NPs) behave with a toxic nature with respect to the growth of cancer cells, as is very clear from the obtained data (Fig. 7 and 8).

As the concentration of NPs increases, the cell apoptosis increases and this resulted in upregulation in mRNA expression. Similar observations were also obtained in the case of caspase 7, when it was introduced after 24 and 72 h incubations in the presence of NPs. In the case of caspase 7 gene expression, at low concentration (100 ng mL^{-1}) of NPs incubated for 24 h, it




Fig. 6 The MTT assay of iron oxide nanoparticles ($\alpha\text{Fe}_2\text{O}_3$ hematite phase) at different concentrations (100 ng mL^{-1} , 500 ng mL^{-1} and 1000 ng mL^{-1}) and incubation (24, 48 and 72 h) times and with a control solution. Experiments were performed in a triplicate manner.




Fig. 7 mRNA expression of C2C12 cells for caspase 3 in the presence of GAPDH genes, with exposure to NPs at low (500 ng mL^{-1}) and high (1000 ng mL^{-1}) concentrations. Experiments were performed in a triplicate manner.

expressed 2.30 and 4.27 fold change respectively, whereas at a higher concentration (1000 ng mL^{-1}) of $\alpha\text{Fe}_2\text{O}_3$ NPs and higher incubation period (72 h), apoptosis changes were 2.26 to 5.83 fold (Fig. 8).⁴⁴

Confocal laser scanning microscopy (CLSM) study effect with $\alpha\text{Fe}_2\text{O}_3$ NPs

The dead and live cells and their morphology in a wet environment were also studied *via* CLSM in a dose-dependent manner with 5% CO_2 for a 24 h incubation period with the staining solution propidium iodide (PI). Fig. 9 shows the effect of different concentrations of $\alpha\text{Fe}_2\text{O}_3$ -NPs from low (100 ng mL^{-1} conc) to high (500 ng mL^{-1} & 1000 ng mL^{-1}). From the images it is clear that at low concentration the toxicity of the nanostructures does not have much effect on the cells, but as the dose of NPs increases (500 ng mL^{-1} & 1000 ng mL^{-1}), more than $\sim 85\text{--}90\%$ of the cells were completely damaged. Our results also corroborated the obtained MTT data (Fig. 6), and define that the toxicity to the cells is dependent on the concentration of utilized NPs and the ageing (incubation period) of the cells. This phenomenon is under investigation and the relation between NPs and cells lines needs to be confirmed.^{40,42,43}




Fig. 8 mRNA expression of C2C12 cells for caspase 7 in the presence of GAPDH genes, with exposure to NPs at low (500 ng mL^{-1}) and high (1000 ng mL^{-1}) concentrations.




Fig. 9 CLSM images of C2C12 cells at different concentrations of $\alpha\text{Fe}_2\text{O}_3$ hematite NPs (100 ng mL^{-1} , 500 ng mL^{-1} and 1000 ng mL^{-1}) with a 24 h incubation period.

Analytical determinations of $\alpha\text{Fe}_2\text{O}_3$ NPs with C2C12 cells

The analytical technique, regulatory markers, utilized a quantity of $\alpha\text{Fe}_2\text{O}_3$ NPs. This study will be helpful to differentiate the NPs before and after mingling with the C2C12 cells ($\alpha\text{Fe}_2\text{O}_3$ NPs C2C12) component. In the present case the quantity of utilized sample and their molecular species absorb radiation with respect to a suitable wavelength (nm) at maximum absorption (λ_{max}). The quality of the analytes (the essential ability of the nanomaterials ($\alpha\text{Fe}_2\text{O}_3$ NPs) to control caspase 3 and 7 genes in C2C12 cells) was analyzed *via* optimization and validation methods. The statistical analytical technique has the ability to provide information about the relation between both chemical and biological quantized species which distinguishes the resulting data. In our results, which are illustrated as Fig. 10(a–c), the absorbance of $\alpha\text{Fe}_2\text{O}_3$ -NPs was displayed at two positions at λ_{max} 220 and 430 nm, whereas the C2C12 and $\alpha\text{Fe}_2\text{O}_3$ -NPs–C2C12 show absorbance at λ_{max} 290 and 360 nm wavelength, respectively. On the basis of the obtained data a calibration graph was constructed for the $\alpha\text{Fe}_2\text{O}_3$ -NPs by plotting absorbance against concentration (conc., 0.5 – $2.0 \text{ } \mu\text{g mL}^{-1}$) which gives a linear graph (Fig. 11). The linear regressive equation ($A = 0.109 + 1.732C$) of the calibration data obtained ($n = 5$) with the help of absorbance *versus* concentration, gives the value of the intercept (a), slope (b), and correlation coefficient.^{45,46} The high molar absorptivity ($\alpha\text{Fe}_2\text{O}_3$ -NPs = $9.20 \times 10^3 \text{ L mol}^{-1} \text{ cm}^{-1}$) of the resulting sample solution indicates the sensitivity, detection limit (LOD) and quantitation limit (LOQ), relative standard deviation (RSD), showing the system suitability of the proposed method at the lowest concentration level.^{47,48} These empirical formulae provided more reliable values to ensure that they are fit for the proposed method and confirmed that this method is accurate, precise, reproducible, and gives adequate results. The recovery and relative standard deviation (RSD) experiments are summarized in Tables S1 and S2.† It is evident from both tables that the recoveries (99.54–100.94%) were almost accurate and were satisfactory.^{47,48}




Fig. 10 The absorption spectra of $\alpha\text{Fe}_2\text{O}_3$ NPs (a), C2C12 cells (b), spectra of $\alpha\text{Fe}_2\text{O}_3$ NPs and C2C12 cells (c).

Possible proposed mechanism

On the basis of obtained data the exact mechanism of cytotoxicity with $\alpha\text{Fe}_2\text{O}_3$ NPs and damage to cells and their organelles is still under debate, but from our observations, such as morphology, cell viability, PCR detection with caspase 3 and 7 genes and CLSM study, we have projected and explained the cause of cell damage with $\alpha\text{Fe}_2\text{O}_3$ -NPs in a possible pictorial mechanism (Fig. 12), relating to cytotoxicity happening with $\alpha\text{Fe}_2\text{O}_3$ -NPs. The toxicity to the cells depends on various types of parameters, such as the size of the nanostructures used, the shape of the material, chemical content, and dose/concentration of NPs, cell concentration *etc.* It also affects the endocytic uptake of cells.^{40,42,43,49} In our case it is assumed that the $\alpha\text{Fe}_2\text{O}_3$ NPs are very small (12–15 nm) and spherical in shape so they can easily enter into the cell membrane because the size of each cell is usually around $\sim 20 \text{ } \mu\text{m}$, which means enough space for the nanostructures to enter into the cells. The $\alpha\text{Fe}_2\text{O}_3$ -NPs first attack the surface of the cancerous cells and then the cell membranes which exhibit small pores/passages in their organization, facilitates entry of small $\alpha\text{Fe}_2\text{O}_3$ NPs into cells and damages the upper layer of the cell walls (as in the schematic in Fig. 12). As with our obtained result at 100 ng




Fig. 11 The linear calibration graph of $\alpha\text{Fe}_2\text{O}_3$ NPs.




Fig. 12 Possible proposed schematic mechanism for the interaction of $\alpha\text{Fe}_2\text{O}_3$ NP against C2C12 and their cytological death.

mL^{-1} concentration of NPs, the density of damaged cells is lower because of the concentration as compared to higher applied doses such as 500 or 1000 ng mL^{-1} concentration of $\alpha\text{Fe}_2\text{O}_3$ NPs. The very small size of the nanoparticles relative to the cell size as well as the high density of $\alpha\text{Fe}_2\text{O}_3$ NPs in liquids can strongly favor the rapid formation of adduct.^{40,42,43,49} It is assumed that adducts formed of $\alpha\text{Fe}_2\text{O}_3$ NPs have the ability to destroy the cell organelles, which ultimately succumb to cell death.

In case of analytical performance, the statistical interpretations and their validation were studied under International Conference of Harmonization (ICH) guidelines. This (ICH) guideline recommends validation characteristics of analytical methods such as: linearity, range, accuracy, precision, repeatability, specificity, LOD and LOQ.^{45,46} The statistical analytical parameters playing an important role in promoting and encouraging the capability of a nanomaterial include the mean, standard deviation, variance and standard analytical error, RSD, coefficient of correlation, regression line, variance, errors in the slope and the intercept, and confidence limit for the slope and the intercept. For the statistical analysis performance an appropriate quantity of $\alpha\text{Fe}_2\text{O}_3$ NPs solution was dedicated to control toxicity in cancerous cells. Therefore, prerequisites, assumptions and formulae were employed at a low concentration level to design an experimental plan for strictly defined standard quantitative and qualitative results to specify reaction conditions. The UV-visible spectrophotometer technique provides absorption spectra in regard to absorbance, and more reliable values of the resulting data confirm the relationship and interaction between $\alpha\text{Fe}_2\text{O}_3$ NPs and C2C12 cancerous cells. The aptitude of the analytical procedure to achieve test results is directly proportional to the concentration of $\alpha\text{Fe}_2\text{O}_3$ NPs in the sample solutions. Beer's law was followed in the concentration range from 0.05 to 1.0 $\mu\text{g mL}^{-1}$ and, therefore, this solution range was fixed for $\alpha\text{Fe}_2\text{O}_3$ NPs (Fig. 10). The linearity represents the ability to use regression equation analysis ($A = -0.109 + 1.732C$) of the calibration data obtained ($n = 5$) with the help of $\alpha\text{Fe}_2\text{O}_3$ NPs absorbance *versus* concentration, which gives the value of the intercept (a), slope (b), apparent molar absorptivity ($\alpha\text{Fe}_2\text{O}_3$ NPs = $9.20 \times 10^3 \text{ L mol}^{-1} \text{ cm}^{-1}$), variance of the slope of the regression line ($\text{So}^2 = 2.04 \times 10^{-4}$), correlation coefficient ($r^2 = 0.9996$), ($\pm t_{\text{Sa}}$

= 0.013 and $\pm t_{\text{Sb}} = 0.024$), limits of detection ($\text{LOD} = 402.5 \mu\text{g mL}^{-1}$) and limit of quantitation ($\text{LOQ} = 1219.7 \mu\text{g mL}^{-1}$) at a 95% confidence level (Table S1†). Accuracy and precision were achieved with replicate sets of $\alpha\text{Fe}_2\text{O}_3$ NPs (analyte) with respect to three concentrations, which represented the entire range of the standard linear curve (Fig. 11). To evaluate intra-day and inter-day precision, analyses of $\alpha\text{Fe}_2\text{O}_3$ NPs at three concentration levels (0.221, 0.732 and 1.125 $\mu\text{g mL}^{-1}$) were carried out within the same day and on five consecutive days. The intra-day and inter-day RSD values for $\alpha\text{Fe}_2\text{O}_3$ NPs ranged from 0.918 to 1.951% and from 1.483 to 1.814%, respectively, and the obtained results are summarized in Table S2.† The % recoveries were quantitative for $\alpha\text{Fe}_2\text{O}_3$ NPs (99.31–100.94%), indicating good accuracy of the proposed method and satisfactory recovery with values of RSD (%) analyzed by a spectrophotometric method. All resulting data conform strictly to statistical analysis and acceptable accuracy and precision under the quantified level to sustain bioavailability with caspase 3 and 7 in C2C12 cells. The reliable results are satisfactory and fully validated according to acceptance criteria from an assay performance of statistical analysis, giving an appropriate quantity of analytes to reduce or control the multiplication of C2C12 cells. The toxicity to biological materials (cancerous cells) was good, supporting the selection of $\alpha\text{Fe}_2\text{O}_3$ NPs, and the species integrity maintained a quantity which allowed the endorsement of standardized nanomaterials for use as a proper essential ingredient at a low limit of quantified levels. Hence, the statistical analytical techniques recommended in the specification validated the resulting data and ensured it achieved a 95% confidence level.^{45–48}

Conclusion

In the present work, we have successfully synthesized spherical shaped $\alpha\text{Fe}_2\text{O}_3$ hematite iron oxide NPs *via* a solution process at low cost. The particles were characterized with the available sophisticated instruments in terms of their crystalline character and morphology, such as X-ray diffraction pattern, FESEM and TEM, respectively. The chemical functional footprints were analysed *via* FTIR spectroscopy. The prepared NPs (~12–15 nm) were utilized to control the proliferation of cancer cells C2C12 cells in a dose-dependent manner. The viability of the cells was examined with MTT assay which revealed that enhanced cell death was caused in a dose-dependent manner, which plays an important role in controlling the density of cells. Included in this study, the density of dead cells in a wet environment was also approved from the CLSM study. The cell apoptosis of C2C12 in the presence of caspases 3 and 7 with GAPDH genes with controlled doses of $\alpha\text{Fe}_2\text{O}_3$ hematite iron oxide NPs was checked with RT-PCR study. To validate the obtained study, an analytical technique was employed in terms of the determination of nanomaterials, selected for reduction in cell viability and controlling the growth of cancerous cells. The applicability of the NPs is the right choice for the purpose of cancerous cell inhibition. The statistical parameters validated the performance, where the suitability, selectivity, sensitivity, rapidity accuracy, and precision were the main advantages of the proposed method. The statistical analytical parameters such as the mean (\bar{X}), standard deviation (SD), relative standard

deviation (RSD) and confidence limit (C.L.) at 95% were calculated in order to verify the validity of the experimental data, to check the anticancerous effects. The small NPs are highly effective against the proliferation rate of cancer cells and the analytical determination techniques define the quality of the results. The obtained statistical results show higher accuracy with reproducibility, as indicated by the qualitative and quantitative results from UV-visible spectroscopy. Under the ICH guidelines, the analytical parameters were authenticated and studied for the validation and standardization of analytical procedures for the approval and authentication of the result.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgements

This study was financially supported by the King Saud University, Vice Deanship of Research Chairs.

References

- 1 A. Akbarzadeh, M. Samiei and S. Davaran, *Nanoscale Res. Lett.*, 2012, **7**, 144.
- 2 M. Marcus, M. Karni, K. Baranes, I. Levy, N. Alon, S. Marge and O. Shefi, *J. Nanobiotechnol.*, 2016, **14**, 37.
- 3 M. Mahmoudi, F. Q. Pluck, M. P. Monopoli, S. Sheibani, H. Vali, K. A. Dawson and I. Lynch, *ACS Chem. Neurosci.*, 2013, **4**(3), 475–485.
- 4 K. K. Atyam, A. Ghosh, K. Mukherjee and S. B. Majumder, Hematite iron oxide nano-particles: facile synthesis and their chemi-resistive response towards hydrogen, *Mater. Res. Express*, 2015, **2**, 055901.
- 5 K. Kim, I. H. Kim, K. Y. Yoon, J. Lee and J. H. Jang, α -Fe₂O₃ on patterned fluorine doped tin oxide for efficient Photo electrochemical water splitting, *J. Mater. Chem. A*, 2015, **3**, 7706–7709.
- 6 L. Cui, D. Zhao, Y. Yang, Y. Wang and X. Zhang, Synthesis of highly efficient α -Fe₂O₃ catalysts for CO oxidation derived from MIL-100 (Fe), *J. Solid State Chem.*, 2017, **247**, 168–172.
- 7 H. Katsuki and S. Komarneni, *J. Am. Ceram. Soc.*, 2003, **86**(1), 183–185.
- 8 Y. Fu, J. Wang, H. Y. Yu, X. Li, H. Wang, J. H. Tian and R. Yang, *Int. J. Hydrogen Energy*, 2017, **42**(32), 20711–20719.
- 9 G. Haiying, J. Tifeng, Z. Qingrui, L. Adan and G. Faming, *Rare Met. Mater. Eng.*, 2015, **44**(11), 2688–2691.
- 10 B. P. Singh, A. Kumar, A. P. Duarte, S. J. Rojas, M. C. Medina, H. I. A. Martinez, C. A. V. Olivencia and M. S. Tomar, *Mater. Res. Express*, 2015, **3**, 106105.
- 11 A. Mirzaei, K. Janghorban, B. Hashemi, A. Bonavita, M. Bonyani, S. G. Leonardi and G. Neri, *Nanomaterials*, 2015, **5**, 737–749.
- 12 H. Niu, S. Zhang, Q. Ma, S. Qin, L. Wan, J. Xu and S. Miao, *RSC Adv.*, 2013, **3**, 17228–17235.
- 13 E. M. Verdugo, Y. Xie, J. Baltrusaitis and D. M. Cwiertny, *RSC Adv.*, 2016, **6**, 99997–100007.
- 14 Z. Ma, X. Huang, S. Dou, J. Wu and S. Wang, *J. Phys. Chem. C*, 2014, **118**(31), 17231–17239.
- 15 Y. M. Lin, P. R. Abel, A. Heller and C. B. Mullins, *J. Phys. Chem. Lett.*, 2011, **2**(22), 2885–2891.
- 16 N. Yan, X. Zhou, Y. Li, F. Wang, H. Zhong, H. Wang and Q. Chen, *Sci. Rep.*, 2013, **3**, 3392.
- 17 J. R. Griffiths and J. D. Glickson, *Adv. Drug Delivery Rev.*, 2000, **41**(1), 75–89.
- 18 M. M. B. Abbad, M. S. Takriff, A. Benamor and A. W. Mohammad, *J. Sol-Gel Sci. Technol.*, 2017, **81**(3), 880–893.
- 19 L. Liu, H. Z. Kou, W. Mo, H. Liu and Y. Wang, *J. Phys. Chem. B*, 2006, **110**(31), 15218–15223.
- 20 M. Tadic, M. Panjan, V. Damnjanovic and I. Milosevic, *Appl. Surf. Sci.*, 2014, **320**, 183–187.
- 21 T. Tsuzuki, F. Schäffel, M. Muroi and P. G. McCormick, *Powder Technol.*, 2011, **210**(3), 198–202.
- 22 A. K. Mondal, S. Chen, D. Su, K. Kretschmer, H. Liu and G. Wang, *J. Alloys Compd.*, 2015, **648**, 732–739.
- 23 S. G. Hosseini and E. Ayoman, *J. Therm. Anal. Calorim.*, 2017, **128**(2), 915–924.
- 24 Z. Pu, M. Cao, J. Yang, K. Huang and C. Hu, *Nanotechnology*, 2006, **17**(3), 799–804.
- 25 A. Lassoued, B. Dkhil, A. Gadri and S. Ammara, *Results Phys.*, 2017, **7**, 3007–3015.
- 26 F. S. Yen, W. C. Chen, J. M. Yang and C. T. Hong, *Nano Lett.*, 2002, **2**(3), 245–252.
- 27 J. A. Morales-Morales, *Ciencia en Desarrollo*, 2017, **8**(1), 99–107.
- 28 K. Shimizu, S. V. Sokolov and R. G. Compton, *Colloid Interface Sci. Commun.*, 2016, **13**, 19–22.
- 29 Q. A. Pankhurst, J. Connolly, S. K. Jones and J. Dobson, *J. Phys. D: Appl. Phys.*, 2003, **36**, R167–R181.
- 30 P. Polak and O. Shefi, *Nanomedicine*, 2015, **11**, 1467–1479.
- 31 A. Ali, H. Zafar, M. Zia, I. Haq, A. R. Phull, J. S. Ali and A. Hussain, *Nanotechnol., Sci. Appl.*, 2016, **9**, 49–67.
- 32 K. Rajendran, V. Karunagaran, B. Mahanty and S. Sen, *Int. J. Biol. Macromol.*, 2015, **74**, 376–381.
- 33 C. A. Pacak, P. E. Hammer, A. A. MacKay, R. P. Dowd, K. R. Wang, A. Masuzawa, B. Sill, J. D. McCully and D. B. Cowan, *PLoS One*, 2014, **9**(9), e108695.
- 34 M. Tadic, L. Kopanja, M. Panjan, S. Kralj, J. N. Runice and Z. Stojanovic, *Appl. Surf. Sci.*, 2017, **403**, 628–634.
- 35 D. Cardillo, M. Tehei, M. S. Hossain, M. M. Islam, K. Bogusz, D. Shi, D. Mitchell, M. Lerch, A. Rosenfeld, S. Corde and K. Konstantinov, *ACS Appl. Mater. Interfaces*, 2016, **8**(9), 5867–5876.
- 36 S. Kanagesan, M. Hashim, S. Tamilselvan, N. B. Alitheen, I. Ismail, A. Hajalilou and K. Ahsanul, *Adv. Mater. Sci. Eng.*, 2013, **201**, 710432.
- 37 A. Yanai, U. O. Hfeli, A. L. Metcalfe, P. Soema, L. Addo, C. Y. G. Evans, K. Po, X. Shan, O. L. Moritz and K. G. Evans, *Cell Transplant.*, 2012, **21**, 1137–1148.
- 38 B. D. Cullity, *Elements of X-Ray Diffraction*, Addison-Wesley, Reading MA, 1978, p. 102.

- 39 W. Cui, J. Li, Y. Zhang, H. Rong, W. Lu and L. Jiang, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2012, **8**(1), 46–53.
- 40 R. Wahab, F. Khan, Y. B. Yang, I. H. Hwang, H. S. Shin, J. Ahmad, S. Dwivedi, S. T. Khan, M. A. Siddiqui, Q. Saquib, J. Musarrat, A. A. Al-Khedhairi, Y. K. Mishra and B. A. Ali, *RSC Adv.*, 2016, **6**, 26111–26120.
- 41 R. Wahab, I. H. Hwang, Y. S. Kim, J. Musarrat, M. A. Siddiqui, H. K. Seo, S. K. Tripathy and H. S. Shin, *Chem. Eng. J.*, 2011, **175**, 450–457.
- 42 R. Wahab, Y. B. Yang, A. Umar, S. Singh, I. H. Hwang, H. S. Shin and Y. S. Kim, *J. Biomed. Nanotechnol.*, 2012, **8**(3), 424–431.
- 43 R. Wahab, S. Dwivedi, F. Khan, Y. K. Mishra, I. H. Hwang, H. S. Shin, J. Musarrat and A. A. Al-Khedhairi, *Colloids Surf., B*, 2014, **123**, 664–672.
- 44 M. W. Pfaffl, *Nucleic Acids Res.*, 2001, **29**(9), e45.
- 45 *International Conference on Harmonisation, Harmonized Tripartite Guideline, Validation of Analytical Procedures. Text and Methodology, Q2 (R1)*, 2005, November, <https://www.ich.Org>.
- 46 P. Yanez-Sedeno, J. Riu, M. J. Pingarron and F. X. Rius, *Trends Anal. Chem.*, 2010, **29**(9), 939.
- 47 L. Chekli, B. Bayatsarmadi, R. Sekine, B. Sarkar, A. M. Shen, K. G. Scheckel, W. Skinner, R. Naidu, H. K. Shon, E. Lombi and E. Donner, *Anal. Chim. Acta*, 2016, **903**, 13–35.
- 48 R. Wahab, F. Khan, Lutfullah, R. B. Singh, N. K. Kaushik, J. Ahmad, M. A. Siddiqui, Q. Saquib, B. A. Ali, S. T. Khan, J. Musarrat and A. A. Al-Khedhairi, *Physica E Low Dimens. Syst. Nanostruct.*, 2015, **69**, 101–108.
- 49 S. Ghosh, K. Das, K. Chakrabartia and S. K. De, *Dalton Trans.*, 2013, **42**, 3434–3446.